A private equity group based in the Eastern US currently has over $9 billion in assets under management, and is currently looking to deploy capital from its fifth fund – which raised over $2 billion – to life science companies.
The firm has no set timeframe to make allocations, but would invest within the next sixth months if a compelling opportunity were identified. The firm’s investments typically range from $30-50 million. The firm is most interested in biotech R&D service firms, and specifically is looking for contract manufacturing organizations (CMOs) and contract research organizations (CROs).
The firm provides firms with growth capital, and also does distressed equity transactions, and therefore is only looking for established firms. The PE has no preference as to where the firm is based, and plans to invest up to 49% of the fund’s assets in firms that are located outside of the US. The firm mainly invests in private companies but will consider public companies as well.
Next Phase Newsletter 
Leave a comment